下一代生物偶联物设计需要正交分析方法
Next-Generation Bioconjugate Design Calls for an Orthogonal Analytical Approach
随着生物偶联物日益复杂,专家讨论正交分析方法如何填补表征缺口。文章聚焦下一代生物偶联物设计对正交分析策略的需求,未涉及具体药品、批次或监管文件。
News|Articles|November 17, 2026
As bioconjugates grow more complex, experts discuss how orthogonal analytical methods fill characterization gaps.
Related to this article
November 18th, 2026
mAbxience will develop and manufacture the antibody for ONC001, a CD64-targeting ADC aimed at monocytic AML and chronic myelomonocytic leukemia.
November 18th, 2026
Verismo will pair Stanford's PACK-IT lentiviral technology with its KIR-CAR platform to pursue off-the-shelf, in vivo CAR T therapies for cancer.
November 18th, 2026
Visara has dosed the first patient in ASCEND, a roughly 244-patient, head-to-head phase 2b trial comparing two doses of its tetravalent VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in treatment-naïve wet AMD. The study will test dosing intervals of up to seven months and select the dose for a global phase 3 program planned as early as 2027.
November 18th, 2026
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.
November 17th, 2026
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.
November 17th, 2026
Marrow's lead candidate MAR-101 aims to reactivate fetal hemoglobin in sickle cell disease and beta thalassemia through in vivo bone marrow targeting.
November 17th, 2026
Merck's Dr Dave Maraldo explains that small-molecule platform agility and flexible conjugation capacity can help biologics manufacturing respond to research needs.
November 17th, 2026
Danish biotech Commit Biologics closed a $60 million seed round led by Ackermans & van Haaren, with AbbVie Ventures and M Ventures joining, to advance COM002, a bispecific antibody that recruits complement rather than T cells to eliminate diseased cells.
来源:BioPharm International · biopharminternational.com







